Over the past decade, CVS Health has invested more than $1.5 million to Easterseals in early childhood services, which has ensured the best possible start in life for tens of thousands of young children. Read More »
Joins experienced management team; will oversee contract sales organization. Read More »
Raptor Pharmaceuticals Corp., a biopharmaceutical company focused on the development and commercialization of transformative treatments to treat rare diseases, has announced its participation in the European Respiratory Society (ERS) International Congress 2016. Read More »
Aclaris announces results of A-101 topical solution to treat the common wart. Read More »
Health Center Partners, a group of community health centers in San Diego, Riverside and Imperial counties in California, recently announced that is has been named the recipient of $1.5 million from the U.S. Department of Health and Human Services (HHS). Read More »
Stanley Crooke, founder, CEO and chairman of Ionis Pharmaceuticals, has been named the recipient of the E. B. Hershberg Award by the American Chemical Society for significant discoveries in medicinally active substances. Read More »
Men who received placebo and subsequent treatment with fexapotide show lower surgery rates. Read More »
A majority of health care plans and programs with a drug exclusion policy have been successful, reducing costs and not negatively impacting patient care, concludes a new study published in The American Journal of Managed Care. Read More »
The CVS Health Research Institute this week released the findings of a new study showing that it is extremely cost-efficient to intervene in order to increase medication adherence in patients suffering from common chronic conditions. Read More »
Perrigo also confirms lawsuit over generic version of Mirvaso topical gel. Read More »
CytoDyn Inc., a company specializing in biotechnology that is dedicated to the development of new antibody therapies for the treatment of human immunodeficiency virus (HIV), recently announced that the first of 11 patients with HIV-1 in its Phase 2b extension study of PRO 140 has achieved two years of complete virologic suppression. Read More »
BPX-01 topical minocycline reduces P. acnes after four weeks without entering bloodstream. Read More »
In the wake of a large jury verdict against Johnson & Johnson, the health products industry is closely watching a debate over expert witness standard legislation in Missouri. Read More »
The board members will use their expertise to guide the company and advance its drug development programs. Read More »
MRG anticipates improvements in customer and patient billing process, regulatory compliance and claims management. Read More »
.jpg)
Supernus Pharmaceuticals Inc. recently reported that its Supplemental New Drug Application (sNDA) that requested an expansion to the label of Trokendi XR to include prophylaxis for migraine headaches in adults has been granted tentative approval by the U.S. Food and Drug Administration (FDA). Read More »
Juniper Pharmaceuticals Inc. announced last week its Phase IIb clinical trial for COL-1077, which was recently completed, did not meet either its primary or secondary goals. Read More »
Phase III trial produces positive results in treating primary biliary cholangitis with Ocaliva. Read More »
Avion Pharmaceuticals this week announced that it has fortified its partnership with Gnosis S.P.A. by agreeing to make Quatrefolic part of its Prenate prescription prenatal vitamin portfolio. Read More »
Pulmatrix this week announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug status for PUR1900, the company’s inhaled drug designed to treat pulmonary fungal infections in patients with cystic fibrosis (CF). Read More »
Alerts Sign-up
